📣 ADDS 2027 Save the Date!

We hope you'll consider joining us for our 5th meeting, ADDS 2027, taking place Feb 8-10, 2027 at the Georgian Terrace Hotel in Atlanta, GA.

NOTE: Our office will be closed Friday, June 19th in observance of Juneteenth. We will reopen at regular business hours on Monday, June 22nd.

Subscribe to Receive Updates

VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials

Durham, NC – January 19, 2021–VeraSci, a global clinical research company offering eClinical...
1 Minute Read
Read More

ActiGraph Promotes Jeremy Wyatt to Chief Executive Officer

Pensacola, FL – June 8, 2020– ActiGraph, a leading provider of medical-grade wearable physical...
1 Minute Read
Read More

snapIoT Announces Another Successful mHealth Integration in One WeekActiGraph/snapClinical Integration Advances Data Collection for Decentralized Clinical Trials

San Diego (PRWEB) MAY 18, 2020:snapIoT announces a successful integration of its mClinical...
2 Minute Read
Read More

ActiGraph Announces Acquisition by ArchiMed

Pensacola, FL – May 18, 2020– ActiGraph, a leading provider of medical-grade wearable physical...
2 Minute Read
Read More

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with integration

Philadelphia, PA – November 14, 2019:Signant Health, formerly CRF Health and Bracket, is proud to...
2 Minute Read
Read More

ActiGraph Partners with VivoSense to Enhance Secure Access to Regulated Sensor Data from Patients in Pharmaceutical Clinical Trials

May 22, 2019, Pensacola, FL – Pensacola, FL–ActiGraph, the leading provider of medical-grade...
2 Minute Read
Read More

ActiGraph Earns ISO-13485:2016/MDSAP Certification

Feb 06, 2019 – Pensacola, FL– ActiGraph announced today that it has earned International...
1 Minute Read
Read More

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients

WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH)...
Read More
1 2 3 4